OOIR: Observatory of International Research

Papers

(The H4-Index of Lancet Rheumatology is 40. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
Real-world evidence for prehospital COVID-19 treatment in systemic autoimmune rheumatic disease	1115
Thrombotic microangiopathy as a presentation of anti-synthetase syndrome	1015
Research in Brief	382
Reigniting the burnt-out health-care workforce	230
Brachial plexopathy: an unusual manifestation of Takayasu arteritis	151
Can contextual factors improve clarity of the results from clinical trials of low back pain?	141
Women in rheumatology in Africa	134
Molecular signature-based decision making in the era of targeted therapies for systemic lupus erythematosus	118
From phenotype to pathophysiology—placing rheumatic diseases in an immunological perspective	115
Acceptability of the COVID-19 vaccine among patients with chronic rheumatic diseases and health-care professionals: a cross-sectional study in 19 Arab countries	90
COVID-19 vaccine-induced T-cell responses in patients with rheumatoid arthritis: preferential induction by ChAdOx1	85
Associations of improvement in laboratory tests with clinical outcomes in patients with active systemic lupus erythematosus: a multinational longitudinal cohort study	84
Three-dimensional, in-vitro approaches for modelling soft-tissue joint diseases	77
Post-COVID condition in patients with inflammatory rheumatic diseases: a prospective cohort study in the Netherlands	77
Biological disease-modification in axial spondyloarthritis: insights from MRI	71
Anti-tumour necrosis factor therapy for early-stage Dupuytren's disease (RIDD): a phase 2b, randomised, double-blind, placebo-controlled trial	70
Dual JAK and ROCK inhibition with CPL'116 in patients with rheumatoid arthritis with inadequate response to methotrexate: a randomised, double-blind, placebo-controlled, phase 2 trial	69
A disseminated gonococcal infection with spinal locations	65
Pathways driving tendinopathy and enthesitis: siblings or distant cousins in musculoskeletal medicine?	61
CAR T-cell therapy in autoimmune diseases: where are we and where are we going?	59
1-year results of treatment with rituximab in polymyalgia rheumatica: an extension study of a randomised double-blind placebo-controlled trial	59
Research in Brief	54
Reclassifying ANCA-associated vasculitis: a focus on kidney disease	53
Outdoor temperatures and Raynaud's phenomenon in patients with systemic sclerosis	50
Early-stage Dupuytren's disease treatment; a promising next step?	50

Assessing glucocorticoid toxicity: are the measures sensitive enough?	50
Interleukin-5 inhibition in eosinophilic granulomatosis with polyangiitis: time for another approach?	48
Immunity after COVID-19 vaccinations in immunocompromised patients with psoriasis	48
Patient-reported outcomes with anifrolumab in patients with systemic lupus erythematosus	48
Preload deficiency as a treatable cause of fatigue and exercise intolerance in SLE	47
Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study	46
First-line biological versus conventional synthetic disease-modifying antirheumatic drug therapy in adult-onset Still's disease: a multicentre, retrospective, propensity weighted cohort study	46
Biosimilars and the era of interchangeability	45
Artificial intelligence and high-dimensional technologies in the theragnosis of systemic lupus erythematosus	45
Sex-related differences in patient characteristics, and efficacy and safety of advanced therapies in randomised clinical trials in psoriatic arthritis: a systematic literature review and meta-analysis	43
Proof-of-concept studies in axial spondyloarthritis: there are no shortcuts	43
Addition of aerobic physical activity to resistance exercise for hip osteoarthritis (PHOENIX): a randomised comparative effectiveness trial	42
Sex as a predictor of clinical phenotype and determinant of immune response in IgG4-related disease: a retrospective study of patients fulfilling the American College of Rheumatology–European League A	42
Correction to Lancet Rheumatol 2026; 8: e5–6	41
The association of outdoor temperature and self-reported Raynaud's phenomenon severity among people with systemic sclerosis: a Scleroderma Patient-centered Intervention Network Cohort study	40
Pain in clinical trials for knee osteoarthritis: estimation of regression to the mean	40